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OBJECTIVE—Hypoglycemia commonly occurs in intensively-
treated diabetic patients. Repeated hypoglycemia blunts counter-
regulatory responses, thereby increasing the risk for further
hypoglycemic events. Currently, physiologic approaches to aug-
ment counterregulatory responses to hypoglycemia have not
been established. Therefore, the speciﬁc aim of this study was to
test the hypothesis that 6 weeks’ administration of the selective
serotonin reuptake inhibitor (SSRI) ﬂuoxetine would amplify
autonomic nervous system (ANS) and neuroendocrine counter-
regulatory mechanisms during hypoglycemia.
RESEARCH DESIGN AND METHODS—A total of 20 healthy
(10 male and 10 female) subjects participated in an initial
single-step hyperinsulinemic (9 pmol  kg
1  min
1)-hypoglyce-
mic (means  SE 2.9  0.1 mmol/l) clamp study and were then
randomized to receive 6 weeks’ administration of ﬂuoxetine (n 
14) or identical placebo (n  6) in a double-blind fashion. After
6 weeks, subjects returned for a second hypoglycemic clamp.
Glucose kinetics were determined by three-tritiated glucose, and
muscle sympathetic nerve activity (MSNA) was measured by
microneurography.
RESULTS—Despite identical hypoglycemia (2.9  0.1 mmol/l)
and insulinemia during all clamp studies, key ANS (epinephrine,
norepinephrine, and MSNA but not symptoms), neuroendocrine
(cortisol), and metabolic (endogenous glucose production, gly-
cogenolysis, and lipolysis) responses were increased (P  0.01)
following ﬂuoxetine.
CONCLUSIONS—This study demonstrated that 6 weeks’ ad-
ministration of the SSRI ﬂuoxetine can amplify a wide spectrum
of ANS and metabolic counterregulatory responses during hypo-
glycemia in healthy individuals. These data further suggest that
serotonergic transmission may be an important mechanism in
modulating sympathetic nervous system drive during hypoglyce-
mia in healthy individuals. Diabetes 57:2453–2460, 2008
S
everal reports have indicated that ﬂuoxetine
could have metabolic effects and inﬂuence carbo-
hydrate metabolism (1–3). In fact, there have
been three case studies reporting the occurrence
of hypoglycemia related to the use of selective serotonin
reuptake inhibitors (SSRIs) in depressed patients with and
without diabetes (4–6). However, although SSRIs are
potent inhibitors of neuronal serotonin uptake, they also
have the ability to block norepinephrine transport (7). This
could increase sympathetic outﬂow activity (2,8). Baudrie
and Chaouloff (9) have previously reported an increased
hyperglycemic response to 2-deoxy-D-glycose in conscious
rats following serotononergic receptor antagonists, imply-
ing increased counterregulation in these animals.
A subsequent study by Perry and Fuller (2) demon-
strated that systemic injection of the SSRI ﬂuoxetine in
rats resulted in threefold increases of hypothalamic nor-
epinephrine release, thereby providing a mechanistic basis
for SSRIs to modulate sympathetic nervous system activ-
ity. A later study by Bymaster et al. (3) examined the
speciﬁcity of ﬁve different SSRIs (ﬂuoxetine, citalopram,
ﬂuvoxamine, paroxetine, and sertraline) to acutely in-
crease the extracellular concentration of serotonin and
norepinephrine in rat forebrains. The study demonstrated
that among the SSRIs examined, only ﬂuoxetine increased
extracellular concentrations of both norepinephrine and se-
rotonin in the rat brains and suggested that ﬂuoxetine may
have differential effects compared with other SSRIs.
Thus, previous information from depressed humans and
physiologic data from healthy rats have provided conﬂict-
ing data concerning possible effects of SSRIs on counter-
regulatory mechanisms. In addition, despite the widespread
clinical use of SSRIs, there have been no clinical studies
evaluating the effects of prolonged administration of these
agents on counterregulatory responses during clamped
hyperinsulinemic hypoglycemia. In the present study, ﬂu-
oxetine was chosen based on the drug’s frequent use in
clinical practice and data demonstrating physiologic ef-
fects on both serotonergic and norepinephrine transport in
rats. The hypoglycemic clamp technique was used to
quantify autonomic nervous system (ANS), neuroendo-
crine, and metabolic counterregulatory mechanisms pro-
spectively before and after 6 weeks’ administration of
ﬂuoxetine in healthy nondepressed individuals.
RESEARCH DESIGN AND METHODS
A total of 20 healthy volunteers (10 male and 10 female) of mean  SE age
29  2 years (range 20–44) with a BMI of 24  3 kg/m
2 and A1C of 5.3  0.1%
(normal range 4–6.5%) were studied. The Zung Self-Rating Depression Scale
(10,11) was completed by each subject to rule out symptoms of clinical
depression. None had a history of epilepsy or any major psychiatric illness.
None were taking any psychotropic medication. Each subject had normal
blood count, plasma electrolytes, and liver and renal function. Three subjects
had a family history of diabetes. All gave written informed consent. Hypogly-
cemia (2.9 mmol/l) and euglycemia (5.0 mmol/l) studies were approved by
the Vanderbilt University Human Subjects Institutional Review Board.
Experimental design. The subjects (n  20) participated in two separate
hypoglycemia studies separated by at least 6 weeks (Fig. 1). Subjects received
the study medication (n  14; 7 male and 7 female) or placebo (n  6; 3 male
and 3 female) in a randomized, double-blind fashion after completion of their
ﬁrst clamp study.
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DIABETES, VOL. 57, SEPTEMBER 2008 2453The subjects were asked to avoid any exercise and consume their usual
weight-maintaining diet for 3 days before each study. Each subject was
admitted to the Vanderbilt General Clinical Research Center on the evening
before an experiment. All subjects were studied after an overnight 10-h fast.
On the morning of each study, two intravenous cannulae were inserted
under 1% lidocaine local anesthesia. One cannula was placed in a retrograde
fashion into a vein on the back of the hand. This hand was placed in a heated
box (55–60°C) so that arterialized blood could be obtained (12). The other
cannula was placed in a large vein in the contralateral arm so that 20% glucose
could be infused via a variable rate volumetric infusion pump (Imed, -San
Diego, CA).
Hypoglycemia experiments. After insertion of venous cannulae, at 0 min, a
primed (18 Ci) continuous infusion (0.18 Ci/min) of high-performance
liquid chromatography (HPLC) puriﬁed [3-
3H] glucose (11.5 mCi  mmol
1 
l
1; Perkin Elmer Life Sciences, Boston, MA) was started. At time 120 min, a
primed constant (9.0 pmol  kg
1  min
1) infusion of insulin (Eli Lilly,
Indianapolis, IN) was started and continued until 240 min. The rate of fall of
glucose was controlled (0.06 mmol/min) and the glucose nadir (2.9 mmol/l)
was achieved using a modiﬁcation of the glucose clamp technique (13,14).
Potassium chloride (20 mmol/l) was infused during the clamp to reduce
insulin-induced hypokalemia. A second identical hyperinsulinemic-hypoglyce-
mic clamp was performed after receiving 6 weeks ’ administration of study
medication.
Study medication. Following the initial clamp study, volunteers were given
either ﬂuoxetine or placebo for 6 weeks. The ﬂuoxetine dose was as follows:
20 mg/day during week 1, 40 mg/day during week 2, 60 mg/day during week 3,
and 80 mg/day during weeks 4–6. Volunteers were blinded as to the treatment
group to which they were assigned. Stratiﬁed block randomization was
performed by the Vanderbilt University Investigational Pharmacy. The sub-
jects were stratiﬁed according to sex because sex is known to affect
counterregulatory responses (15). Randomization was performed within each
sex, and blocks of two were used to ensure an equal number of male and
female subjects in the placebo and ﬂuoxetine treatment groups. The study was
powered at n  14 for the ﬂuoxetine group. When we reached this total, it
became obvious that there were clear statistical differences between the
groups, and it was not necessary to study additional placebo subjects. The
placebo group was used primarily as a time control to demonstrate that
counterregulatory responses to hypoglycemia in our normal subjects had not
changed during the 6-week study period or that involvement in the experi-
mental protocol did not inﬂuence physiologic responses to hypoglycemia.
During the 6-week treatment period, volunteers came to the Vanderbilt
General Clinical Research Center once a week for monitoring of compliance
and adverse events. Compliance was determined via a pill count and a blood
draw to measure serum ﬂuoxetine levels. One subject in the placebo group
withdrew from the study because of perceived side effects of the treatment.
After taking either placebo or ﬂuoxetine for 6 weeks, subjects underwent
another single-day hypoglycemic clamp study as previously described. Upon
completion of this second 1-day study, subjects were tapered off the study
medication (placebo or ﬂuoxetine). Those randomized to ﬂuoxetine received
40 mg/day for 1 week and 20 mg/day for a second week. Once subjects ﬁnished
the medication, they were unblinded to the medication they had taken.
Direct measurement of muscle sympathetic nerve activity. Muscle
sympathetic nerve activity (MSNA) was recorded from the peroneal nerve at
the level of the ﬁbular head and popliteal fossa (16,17). The approximate
location of this nerve was determined by transdermal electrical stimulation to
produce painless muscle contraction of the foot. Following this, a reference
stainless steel microelectrode with a shaft diameter of 200 m was placed
subcutaneously. A similar tungsten electrode, with an uninsulated tip, was
inserted into the nerve and used for recording of MSNA.
Nerve activity was recorded on a PC-based Windaq data acquisition system
at 1,000 H2Z channel
1 (DATAQ Instruments, Akron, OH). We analyzed 5-min
Windaq ﬁles with a MatLab GUIDE interface (to adjust for an individual’s 1.3-s
nerve burst delay from a 1-removed R-R interval, automatically detected by
pulse synchronicity, a 2:1 signal-to-noise ratio, and wave-form shape). Further
criteria for acceptable MSNA recordings were the following: 1) electrical
stimulation produced muscle twitches but not paresthesia, 2) nerve activity
increased during phase II of the Valsalva maneuver (hypotensive phase) and
was suppressed during phase IV (blood pressure overshoot), and 3) nerve
activity increased in response to held expiration.
Tracer calculations. Rates of glucose appearance (Ra), endogenous glucose
production (EGP), and glucose utilization were calculated according to the
methods of Wall et al. (18). EGP was calculated by determining the total Ra
(comprising both EGP and any exogenous glucose infused to maintain the
desired hypoglycemia) and subtracting it from the amount of exogenous
glucose infused. It is now recognized that this approach is not fully quantita-
tive because underestimates of total Ra and rate of glucose disposal (Rd) can
be obtained. The use of a highly puriﬁed tracer and taking measurements
under steady-state conditions (i.e., constant speciﬁc activity) in the presence
of low glucose ﬂux eliminate most, if not all, of the problems. In addition, to
maintain a constant speciﬁc activity, isotope delivery was increased commen-
surate with increases in exogenous glucose infusion. During these studies,
only glucose ﬂux results from the steady-state basal and the ﬁnal 30-min
periods of the hypoglycemic clamps are reported.
Analytical methods. Plasma glucose concentrations were measured in
triplicate using the glucose oxidase method with a glucose analyzer (Beck-
man, Fullerton, CA). Glucagon and insulin were measured as previously
described (19,20) with an interassay coefﬁcients of variation (CVs) of 12 and
9%, respectively. Catecholamines were determined by HPLC (21) with an
interassay CV of 12% for epinephrine and 8% for norepinephrine. Cortisol was
assayed using the Clinical Assays Gamma Coat Radioimmunoassay kit with an
interassay CV of 6%. Growth hormone and pancreatic polypeptide levels were
determined by radioimmunoassay (22,23) with CVs of 8.6 and 8.0%, respec-
tively. Lactate, glycerol, alanine, and -hydroxybutyrate were measured in
deproteinized whole blood using the method of Lloyd et al. (24). Nonesteriﬁed
fatty acids (NEFAs) were measured using the WAKO kit adopted for use on a
centrifugal analyzer (25). A1C was determined in whole blood using the
Variant II A1C cation-exchange HPLC kit system (26). Fluoxetine and norﬂu-
oxetine were determined by gas chromatography with electron-capture de-
tection based on a modiﬁcation described by Torok-Both et al. (27).
Blood was drawn for hormones and intermediary metabolites twice during
the control period and every 15 min during the experimental period. Cardio-
vascular parameters (pulse, systolic blood pressure, diastolic blood pressure,
and mean arterial pressure) were measured noninvasively by a Dinamap
(Critikon, Tampa, FL) every 10 min throughout each study.
Hypoglycemic symptoms were quantiﬁed using a previously validated
questionnaire using the model of Deary et al. (28). Each individual was asked
to rate his/her experience of the symptoms twice during the control period
and every 15 min during experimental periods.
Statistical analysis. Data are expressed as means  SE and were analyzed
using standard, parametric, and one- and two-way ANOVA and with repeated
measures where appropriate (SigmaStat; SPSS Science, Chicago, IL). Tukey’s
post hoc analysis was used to delineate statistical signiﬁcance across time
within each group and for each group compared with the control group. A P
value of 0.05 was accepted as statistically signiﬁcant. Baseline hypoglycemic
clamp data represent an average of time points (110 and 120 min), and the ﬁnal
30-min data from each clamp represent an average of three measurements at
210, 225, and 240 min.
Materials. HPLC-puriﬁed [3-
3H] glucose (New England Nuclear, Boston, MA)
was used as the glucose tracer (11.5 mCi  mmol
1  l
1). Human regular
insulin was purchased from Eli Lilly (Indianapolis, IN).
RESULTS
Glucose, insulin, and ﬂuoxetine levels. Basal plasma
glucose levels were 5.3  0.2 mmol/l during the preﬂuox-
etine study and 5.1  0.06 mmol/l during the postﬂuox-
etine study. Weight was unchanged during both the 6-week
ﬂuoxetine (71.1  3.3 to 70.0  3.2 kg) and placebo (74.5 
6.1 to 74.8  5.4 kg) studies. Plasma glucose levels reached
steady state by 30 min, and identical hypoglycemia was
maintained with plasma glucose levels of 2.9  0.05
Protocol  # 1
3-3H glucose
Insulin 9 pmol/kg/min
Plasma glucose 2.9 mmol/L
MICRONEUROGRAPHY
Protocol #2
3-3H glucose
Insulin 9 pmol/kg/min
Plasma glucose 2.9 mmol/L
MICRONEUROGRAPHY
After 6 weeks treatment
Week 4-6       80 mg
Randomized to 6 weeks of :
Placebo          
N=6
Fluoxetine    
N=14
Protocol  # 1
3-3
24 h r s 0
H glucose
Insulin 9 pmol/kg/min
Plasma glucose 2.9 mmol/L
MICRONEUROGRAPHY
Protocol #2
3-3H glucose
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Plasma glucose 2.9 mmol/L
MICRONEUROGRAPHY
After 6 weeks treatment
Week 4-6       80 mg
Week 3          60 mg
Week 2          40 mg
Week 1          20 mg
Randomized to 6 weeks of :
Placebo          
N=6
Fluoxetine    
N=14
FIG. 1. Schematic diagram of experimental protocol.
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2). Basal and steady-state insulin levels for both ﬂuoxetine
and placebo groups were similar during both pretreatment
(43  6 and 631  30 pmol/l, respectively) and postﬂuox-
etine and -placebo (37  6 and 567  30 pmol/l; 35  12
and 559  78 pmol/l, respectively) clamp studies (Fig. 2).
Mean ﬂuoxetine and norﬂuoxetine levels at the end of the
study were 336.7  61 and 230  41 ng/ml, respectively, in
the SSRI group and were undetectable in the placebo
group.
Neuroendocrine counterregulatory hormones. Epi-
nephrine responses were signiﬁcantly higher (8,187 
1,365 pmol/l; P  0.001) during the ﬁnal 30 min of
hypoglycemia postﬂuoxetine compared with those pre-
treatment (5,065  797 pmol/l) and following placebo
(4,366  508 pmol/l). Epinephrine responses were similar
(4,366  508 vs. 5,065  797 pmol/l) during the ﬁnal 30 min
postplacebo compared with those associated with pre-
treatment hypoglycemic clamps (Fig. 3).
Norepinephrine responses were signiﬁcantly higher
(2.4  0.2 nmol/l) during the ﬁnal 30 min of postﬂuoxetine
as compared with those measured during the pretreatment
(1.8  0.2 nmol/l) and placebo (1.2  0.1 nmol/l) (P  0.01)
hypoglycemic clamps. Norepinephrine responses during
hypoglycemia following placebo were similar to pretreat-
ment values and signiﬁcantly reduced compared with
those of the ﬂuoxetine group (Fig. 3).
Basal cortisol levels were signiﬁcantly increased (P 
0.05) in the ﬂuoxetine group (552  55 nmol/l) compared
with those in the pretreatment and placebo groups (359 
27 and 304  55 nmol/l, respectively). Plasma cortisol
responses were also signiﬁcantly higher (1,242  110 and
883  55 nmol/l; P  0.01) during the ﬁnal 30 min of
postﬂuoxetine versus pretreatment and following placebo
(678  79 nmol/l). However, no signiﬁcant differences
occurred in the placebo group (Fig. 3).
Peak pancreatic polypeptide levels during hypoglycemia
increased to 214  54 nmol/lafter ﬂuoxetine administra-
tion compared with pretreatment values (149  22 nmol/l)
(P  0.06). Pancreatic polypeptide levels during the ﬁnal
30 min of hypoglycemia postﬂuoxetine were signiﬁcantly
increased compared with postplacebo values (165  19 vs.
122  17 nmol/l, respectively; P  0.01).
Glucagon responses were similar during hypoglycemia
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FIG. 3. Plasma epinephrine and norepinephrine levels (means  SE) during hyperinsulinemic-hypoglycemic (2.9  0.1 mmol/l) clamp studies in
20 (10 male and 10 female) patients before and after 6 weeks of ﬂuoxetine administration (SSRI) or placebo. Plasma epinephrine and
norepinephrine levels were signiﬁcantly increased (P < 0.01) following ﬂuoxetine compared with pretreatment and placebo values.
Plasma glucagon and cortisol levels (means  SE) during hyperinsulinemic-hypoglycemic (2.9  0.1 mmol/l) clamp studies in 20 (10 male and
10 female) patients before and after 6 weeks of ﬂuoxetine administration (SSRI) or placebo. Plasma cortisol levels are signiﬁcantly increased
(P < 0.01) following ﬂuoxetine administration.
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Fluoxetine had no effect on growth hormone responses
during hypoglycemia. Growth hormone increased from
2  1t o2 8 6 ng/l pretreatment, 2  1t o2 9 7 ng/l
posttreatment, and 2.5  1t o2 1 7 ng/l during placebo.
Glucose kinetics. Glucose speciﬁc activity (disintegra-
tions per minute per milligram) was in a steady state
during the basal period and the ﬁnal 30 min of all hyper-
insulinemic-hypoglycemic clamps (Table 1). During the
ﬁnal 30 min of hypoglycemia, exogenous glucose infusion
rates were signiﬁcantly less in the ﬂuoxetine group (post-
treatment 1.1  0.5 mol  kg
1  min
1 vs. both preﬂuox-
etine 3.1  1.1 and postplacebo 5.5  1.7 mol  kg
1 
min
1; P  0.01). For the placebo group, exogenous
glucose infusion rates were not signiﬁcantly changed
(pretreatment 3.3  1.1 vs. postplacebo 5.5  1.7 mol 
kg
1  min
1). The EGP response in postﬂuoxetine (14 
1.1 mol  kg
1  min
1) was signiﬁcantly increased (P 
0.01) compared with both pretreatment (10.3  1.1) and
postplacebo (9  1.1 mol  kg
1  min
1) levels. The EGP
in the postplacebo group was similar to that pretreatment
9  1.1 vs. 10.3  1.1 mol  kg
1  min
1. The Rd during
the ﬁnal 30 min of hypoglycemia was not signiﬁcantly
changed as a result of receiving 6 weeks ’ administration of
ﬂuoxetine (Fig. 4).
MSNA. MSNA increased by a signiﬁcantly greater amount
(P  0.05) during hypoglycemia in the postﬂuoxetine
group (19  3 bursts/min) compared with both pretreat-
ment (13  3 bursts/min) and postplacebo (14  3
bursts/min) groups. There were no differences in the
TABLE 1
Glucose speciﬁc activity (dpm/mmol) during the basal period and the ﬁnal 30 min of all hyperinsulinemic-hypoglycemic clamps in
nondiabetic individuals before and after 6 weeks of ﬂuoxetine treatment or placebo
20 min 10 min 0 min 90 min 105 min 120 min
Pretreatment 432  21 428  22 417  18 257  18 254  17 254  16
Postﬂuoxetine 443  20 452  20 437  21 279  23 286  27 277  24
Postplacebo 408  36 415  38 401  38 234  22 219  18 216  16
Data are means  SD.
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3 bursts/min, respectively).
Intermediary metabolism. Baseline glycerol, lactate,
-hydroxybutyrate, NEFA, and alanine levels were similar
among the groups (Table 2). The increase in glycerol
during hypoglycemia (19  4 mol/l) was signiﬁcantly
greater (P  0.05) following ﬂuoxetine compared with
pretreatment (12  3 mol/l) or postplacebo (10  2
mol/l values. There was no difference in the increase of
glycerol during hypoglycemia in the placebo group.
Blood lactate was signiﬁcantly increased during the ﬁnal
30 min of hypoglycemia in the postﬂuoxetine group versus
pretreatment and placebo groups (1.8  0.2 vs. 1.3  0.08
and 1.1  0.1 mmol/l, respectively; P  0.05). No signiﬁ-
cant changes occurred in the control group (postplacebo
1.1  0.09 vs. pretreatment 1.3  0.08 mmol/l).
-Hydroxybutyrate levels were also signiﬁcantly higher
in the postﬂuoxetine group versus pretreatment and pla-
cebo groups (0.27  0.01 vs. 0.015  0.01 and 0.017 
0.01mmol/l, respectively; P  0.05). No differences oc-
curred in the pre- and postplacebo group (0.015  0.01 vs.
0.017  0.01 mmol/l, respectively). There was a trend for a
greater reduction in NEFA levels during pretreatment
(276  40 as compared with postﬂuoxetine 192  25; P 
0.069).
Cardiovascular parameters. Basal heart rate and blood
pressure were not different after 6 weeks’ administration
of ﬂuoxetine. Heart rate was signiﬁcantly higher during the
ﬁnal 30 min of postﬂuoxetine compared with that in the
pretreatment and placebo groups (79  6 vs. 69  3 and
70  5 bpm, respectively; P  0.05). No signiﬁcant
differences in heart rate were noted for the control group
(70  5 postplacebo vs. 69  3 bpm pretreatment).
Systolic blood pressure was also signiﬁcantly increased
during hypoglycemia in the postﬂuoxetine group versus
the pretreatment and placebo groups (129  6 vs. 121  5
and 118  6 mmHg, respectively; P  0.05). There were no
differences in the increase of systolic blood pressure in the
placebo group (118  6 vs. 121  5 mmHg). No signiﬁcant
changes in diastolic blood pressure occurred in the exper-
imental or placebo groups (Table 3).
Symptom response. There were no differences in total
symptom scores in the ﬂuoxetine group compared with
either the pretreatment or control groups (autonomic
symptoms 10  2 pretreatment vs. 8  1 posttreatment;
neuroglycopenic scores 14  3 pretreatment and 11  1
posttreatment). Symptoms increased similarly in the
postplacebo control group compared with those in the
pretreatment clamp study (Fig. 5).
DISCUSSION
This study investigated hypoglycemic counterregulatory
responses following 6 weeks’ chronic administration of ﬂu-
oxetine in nondiabetic, nondepressed individuals. We deter-
mined that plasma concentrations of key neuroendocrine
ANS and metabolic counterregulatory responses were in-
creased during the ﬁnal 30 min of clamped moderate hypo-
glycemia following high-dose ﬂuoxetine administration. Key
counterregulatory mechanisms (ANS, hypothalamic pituitary
adrenal, EGP, glycogenolysis, and lipolysis) were signiﬁ-
cantly ampliﬁed following ﬂuoxetine.
Six weeks’ administration of ﬂuoxetine at a stepped
dose to 80 mg/day resulted in a substantial increase in
most, but not all, ANS responses to hypoglycemia. Plasma
epinephrine, norepinephrine, pancreatic polypeptide, and
MSNA levels were increased by 25–50% following ﬂuox-
etine. ANS drive was increased during hypoglycemia but
not during basal conditions. This indicates that the SSRI
did not produce a chronic overstimulation of the sympa-
thetic nervous system, particularly evidenced by no in-
crease in basal heart rate, systolic blood pressure,
norepinephrine, or MSNA levels. The ﬂuoxetine-increased
sympathetic nervous system drive during hypoglycemia
therefore appears to be due to an ampliﬁcation of usual
physiologic responses rather than modulation of basal
homeostatic mechanisms. Sympatho-adrenal, sympathetic
neural, and MSNA response were all ampliﬁed following
ﬂuoxetine. This was distinct to ﬂuoxetine’s effects on
TABLE 3
Cardiovascular responses during hyperinsulinemic-hypoglyce-
mic clamp studies in nondiabetic individuals before and after 6
weeks of ﬂuoxetine or placebo
Basal
period
Final
30 min
Heart rate (beats/min)
Pretreatment 62  36 9  3
Postﬂuoxetine 62  47 9  6*
Postplacebo 59  47 0  5
Systolic blood pressure (mmHg)
Pretreatment 116  3 121  5
Postﬂuoxetine 115  4 129  6*
Postplacebo 111  6 118  6
Diastolic blood pressure (mmHg)
Pretreatment 67  26 1  2
Postﬂuoxetine 69  26 5  2
Postplacebo 63  25 9  4
Data are means  SE. *Signiﬁcantly increased response during the
ﬁnal 30 min of hypoglycemia following 6 weeks of ﬂuoxetine
administration (*P  0.05).
TABLE 2
Plasma glycerol, lactate, ß-hydroxybutyrate, NEFA, and alanine
levels during the basal period and the ﬁnal 30 min of hyperinsu-
linemic-hypoglycemic clamp studies in nondiabetic individuals-
before and after 6 weeks of ﬂuoxetine treatment or placebo
Basal
period
Final
30 min
Glycerol (mmol/l)
Pretreatment 50  36 2  6
Postﬂuoxetine 64  98 2  11*
Postplacebo 90  21 100  23
Lactate (mmol/l)
Pretreatment 0.5  0.07 1.3  0.08
Postﬂuoxetine 0.6  0.09 1.8  0.2*
Postplacebo 0.5  0.13 1.1  0.09
ß-Hydroxybutyrate (mol/l)
Pretreatment 0.03  0.01 0.015  0.01
Postﬂuoxetine 0.06  0.02 0.027  0.01*
Postplacebo 0.095  0.04 0.017  0.01
NEFA (mol/l)
Pretreatment 390  53 114  13
Postﬂuoxetine 332  45 141  22
Postplacebo 308  87 95  20
Alanine (mol/l)
Pretreatment 0.22  0.03 0.21  0.01
Postﬂuoxetine 0.24  0.02 0.24  0.02
Postplacebo 0.26  0.05 0.24  0.03
Data are means  SE. *A signiﬁcantly increased response during the
ﬁnal 30 min of hypoglycemia following 6 weeks of ﬂuoxetine
administration (*P  0.05).
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levels and responses of the hormone during hypoglycemia.
The increased sympathetic nervous system drive resulted
in signiﬁcant ampliﬁcation of metabolic homeostatic
mechanisms during hypoglycemia. Of note, glucose kinet-
ics were profoundly inﬂuenced by ﬂuoxetine administra-
tion. In particular, EGP was strikingly elevated by
ﬂuoxetine. During prolonged hypoglycemia, the ability to
defend against a reduced glucose level depends on the
balance of increasing glucose production and limiting
glucose utilization. Typically, during hypoglycemia that
occurs in patients with type 1 diabetes, it is the restriction
of glucose uptake that is the major homeostatic mecha-
nism, as there is little or no EGP in these individuals.
Fluoxetine administration resulted in a small reduction in
glucose uptake but a signiﬁcant ampliﬁcation of EGP. This
latter response may have been as a result of the combina-
tion of the elevated basal cortisol and ampliﬁed cat-
echolamines during hypoglycemia (29). Key metabolic
counterregulatory mechanisms such as lipolysis (in-
creased glycerol responses), glycogenolysis (increased
lactate), and ketogenesis were all elevated by the ampli-
ﬁed sympathetic nervous system response caused by
ﬂuoxetine. The major regulation of glucose kinetics during
hypoglycemia in long-standing type 1 diabetic and insulin-
deﬁcient type 2 diabetic patients revolves around a func-
tioning sympathetic nervous system. Glucagon responses
to hypoglycemia in type 1 diabetes are typically lost after
only 5 years’ duration and are also signiﬁcantly reduced in
long-standing type 2 diabetes (30). Thus, the sympathetic
nervous system and epinephrine become the principle
defense against a falling plasma glucose level. In the
present study, epinephrine responses were increased by
chronic ﬂuoxetine therapy, whereas the placebo control
had no effect on responses of the catecholamine during
hypoglycemia. Norepinephrine and MSNA responses dur-
ing hypoglycemia were also similarly increased following
ﬂuoxetine, thus indicating a widespread ampliﬁcation of
the sympathetic neural and sympatho-adrenal responses.
Of particular note, however, were the intriguing ﬁndings
regarding the lack of an increase in autonomic symptoms
despite very large increases in sympathetic nervous sys-
tem activity following ﬂuoxetine.
The origin of hypoglycemic symptoms during hypogly-
cemia is complex. Previous studies demonstrated scenar-
ios whereby discordant responses between autonomic
symptoms and catecholamine responses can exist during
hypoglycemia (17,31–33). Generally, studies have deter-
mined that autonomic symptoms can be preserved despite
reduced activity in other branches of the sympathetic
nervous system. For example, DeRosa et al. (31) demon-
strated that symptom responses are preserved in adrena-
lectomized subjects who have no measurable epinephrine
levels during hypoglycemia. Additionally, Aftab-Guy et al.
(34,35) demonstrated that high levels of plasma epineph-
rine mimicking values observed during moderate hypogly-
cemia only produce minor increases in hypoglycemic
symptoms. These studies are examples from a large body
of work demonstrating that hypoglycemic symptoms are
generated primarily from central ANS drive and end-organ
responses. There are also data indicating that hypoglyce-
mic symptoms can be inﬂuenced independently by other
components of the ANS during hypoglycemia. Dagogo-
Jack et al. (32) demonstrated that hypoglycemic symp-
toms can increase before adrenomedullary or sympathetic
neural responses in patients with hypoglycemia-associated
autonomic failure (32). Sandoval et al. (33) and Davis et al.
(17) also demonstrated that hypoglycemic symptoms are
preserved relative to blunting of other ANS responses
following antecedent stress. Thus, previous studies seem
to indicate that hypoglycemic symptoms are resultant of
central ANS drive and are preserved high in the hierarchy
of ANS responses to hypoglycemia. Our ﬁnding, therefore,
of a relatively reduced symptom response (20%) follow-
ing ﬂuoxetine in the context of a generalized increased
(50–60%) ANS drive (MSNA, epinephrine, norepineph-
rine, and pancreatic polypeptide) is interesting and unex-
pected. This may indicate a role for serotonergic pathways
PRE-TREATMENT
POST FLUOXETINE
POST PLACEBO
0
5
10
15
20
25
Final 30 Min of Hypoglycemia
∆
M
S
N
A
 
(
b
u
r
s
t
s
/
m
i
n
)
PRE-TREATMENT
POST FLUOXETINE
POST PLACEBO
0
10
20
30
Final 30 Min of Hypoglycemia
T
o
t
a
l
 
S
y
m
p
t
o
m
s
*
A B
FIG. 5. A: MSNA during the ﬁnal 30 min of hyperinsulinemic-hypoglycemic (2.9  0.1 mmol/l) clamp studies in 20 (10 male and 10 female)
patients before and after 6 weeks of ﬂuoxetine administration (SSRI) or placebo. MSNA levels were signiﬁcantly increased (P < 0.05) following
6 weeks’ ﬂuoxetine administration. B: Total symptom scores during the ﬁnal 30 min of hypoglycemic clamp studies in 20 (10 male and 10 female)
patients before and after 6 weeks of ﬂuoxetine administration (SSRI) or placebo. Data are means  SE.
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healthy man.
The neural mechanisms responsible for ﬂuoxetine’s
effects on amplifying counterregulatory responses to hy-
poglycemia are not evident from this study. Numerous
studies have demonstrated interactions between seroto-
nergic (both 5-HT1A and 5-HT3) and catecholamine neu-
rotransmission pathways in multiple areas of the brain (8).
These include forebrain (thalamus and hypothalamus) and
hindbrain nuclei that are known to play important roles in
regulating ANS responses during hypoglycemia. Carvalho
et al. (36) demonstrated that third-ventricle injections of
ﬂuoxetine in wistar rats resulted in hyperglycemia without
accompanying hyperinsulinemia. Pretreatment with a se-
lective corticotropin-releasing hormone (CRH) antagonist
prevented the increase in hyperglycemia. These data sup-
port a role for ﬂuoxetine in increasing CRH levels, which
can modulate metabolism via increases in sympathetic
nervous system outﬂow (i.e., hyperglycemia independent
of hyperinsulinemia that was suppressed by elevated
sympathetic nervous system activity [32]). An earlier study
by Chaouloff et al. (37) also demonstrated a role in central
serotonergic receptors in the regulation of adrenal cate-
cholamine release. Subsequently, Durand et al. (38) re-
ported that repeated ﬂuoxetine administration can result
in increased adrenal weight and ampliﬁed corticosteroid
responses to stress in certain strains of conscious rats .
Thus, the above studies document a role for the interac-
tion of central serotonegic receptors and 1) hypothalamo-
pituitary-adrenal axis and 2) sympathetic outﬂow in rats
that may provide a mechanistic basis for the novel ﬁndings
of the present study in humans. It should be noted that
ﬂuoxetine had little or no effect on amplifying glucagon
responses during hypoglycemia. This has some relevance,
as glucagon is an important component of the normal
counterregulatory response to falling plasma glucose and
there are data demonstrating that ANS can regulate gluca-
gon release during hypoglycemia (39).
The present study has provided a proof of principle in
evaluating the integrated physiologic effects of the SSRI
ﬂuoxetine on counterregulatory responses during hypogly-
cemia. Despite the ﬁndings of signiﬁcant ampliﬁcation of
ANS and metabolic counterregulatory responses following
ﬂuoxetine, we should note some particular aspects of the
study design. The dose of ﬂuoxetine used in this study was
increased to 80 mg over a 6-week period and is larger than
often used in clinical practice. Despite this, the drug was
well tolerated, with 33% of subjects reporting a transient
reduction of appetite and mild nausea; however, body
weight was unchanged from start to end of the study. One
other subject receiving ﬂuoxetine experienced some sex-
ual dysfunction, and one subject on placebo reported vivid
dreams. Side effects had abated by the ﬁnal 2 weeks of
ﬂuoxetine administration. Additionally, the healthy volun-
teers recruited into this study were screened to have no
depression or depressive symptoms. Furthermore, ﬂuox-
etine had no effects on amplifying hypoglycemic symp-
toms during hypoglycemia.
In summary, this study demonstrated that 6 weeks’
administration of ﬂuoxetine can profoundly increase key
autonomic nervous system (epinephrine, norepinephrine,
pancreatic polypeptide, and MSNA), metabolic (EGP, li-
polysis, and glycogenolysis), and cardiovascular counter-
regulatory responses during clamped moderate (2.9
mmol/l) hypoglycemia. This study also demonstrates the
importance of serotonergic mechanisms in regulating ANS
and hypothalamo-pituitary-adrenal physiologic responses
during hypoglycemia in healthy people. In conclusion,
these results have provided novel ﬁndings demonstrating
that serotonergic transmission may be an important mech-
anism in modulating ANS drive during hypoglycemia in
healthy people.
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